Stocks · News reference

Royalty Pharma Announces $100M Agreement To Acquire Zealand Pharma's Rusfertide Economics, Including 1% Global Royalty; $50M At Closing, $50M On First Anniversary

Aug 12, 2026, 8:23 PMBenzinga Newsdesk

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 12, 2026, 8:23 PM
Checked: Aug 12, 2026, 8:23 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 8, 2026, 2:48 PMBenzinga Newsdesk
Royalty Pharma shares are trading lower amid sympathy with Novartis after that company's pelacarsen phase III trial failed to reach its primary endpoint. The company had signed a $500 million funding agreement with Novartis partner Ionis that would have contributed pelacarsen royalties.
RPRX
BenzingaSep 8, 2026, 2:19 PMKaustubh Bagalkote
Why Is Eli Lilly Stock Falling Tuesday?
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
FTXH IONS LLY NVS PCLG
BenzingaSep 8, 2026, 2:13 PMBenzinga Newsdesk
TD Cowen Maintains Buy on Royalty Pharma, Raises Price Target to $68
RPRX
BenzingaSep 8, 2026, 12:01 PMVandana Singh
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.
IONS NVS RPRX